Literature DB >> 17704148

Biophysical characterization of anticoagulant hemextin AB complex from the venom of snake Hemachatus haemachatus.

Yajnavalka Banerjee1, Rajamani Lakshminarayanan, Subramanian Vivekanandan, Ganesh Srinivasan Anand, Suresh Valiyaveettil, R Manjunatha Kini.   

Abstract

Hemextin AB complex from the venom of Hemachatus haemachatus is the first known natural anticoagulant that specifically inhibits the enzymatic activity of blood coagulation factor VIIa in the absence of factor Xa. It is also the only known heterotetrameric complex of two three-finger toxins. Individually only hemextin A has mild anticoagulant activity, whereas hemextin B is inactive. However, hemextin B synergistically enhances the anticoagulant activity of hemextin A and their complex exhibits potent anticoagulant activity. In this study we characterized the nature of molecular interactions leading to the complex formation. Circular dichroism studies indicate the stabilization of beta-sheet in the complex. Hemextin AB complex has an increased apparent molecular diameter in both gas and liquid phase techniques. The complex formation is enthalpically favorable and entropically unfavorable with a negative change in the heat capacity. Thus, the anticoagulant complex shows less structural flexibility than individual subunits. Both electrostatic and hydrophobic interactions are important for the complexation; the former driving the process and the latter helping in the stabilization of the tetramer. The tetramer dissociates into dimers and monomers with the increase in the ionic strength of the solution and also with increase in the glycerol concentration in the buffer. The two dimers formed under each of these conditions display distinct differences in their apparent molecular diameters and anticoagulant properties. Based on these results, we have proposed a model for this unique anticoagulant complex.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17704148      PMCID: PMC2084224          DOI: 10.1529/biophysj.106.100164

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  54 in total

1.  Proteinminus signProtein Interactions: Interface Structure, Binding Thermodynamics, and Mutational Analysis.

Authors:  Wesley E. Stites
Journal:  Chem Rev       Date:  1997-08-05       Impact factor: 60.622

2.  An extensive interaction interface between thrombin and factor V is required for factor V activation.

Authors:  T Myles; T H Yun; S W Hall; L L Leung
Journal:  J Biol Chem       Date:  2001-04-18       Impact factor: 5.157

3.  Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty.

Authors:  Arno H M Moons; Ron J G Peters; Nick R Bijsterveld; Jan J Piek; Martin H Prins; George P Vlasuk; William E Rote; Harry R Büller
Journal:  J Am Coll Cardiol       Date:  2003-06-18       Impact factor: 24.094

Review 4.  Anticoagulant proteins from snake venoms: structure, function and mechanism.

Authors:  R Manjunatha Kini
Journal:  Biochem J       Date:  2006-08-01       Impact factor: 3.857

5.  Hemextin AB complex, a unique anticoagulant protein complex from Hemachatus haemachatus (African Ringhals cobra) venom that inhibits clot initiation and factor VIIa activity.

Authors:  Yajnavalka Banerjee; Jun Mizuguchi; Sadaaki Iwanaga; R Manjunatha Kini
Journal:  J Biol Chem       Date:  2005-10-04       Impact factor: 5.157

Review 6.  Win some, lose some: enthalpy-entropy compensation in weak intermolecular interactions.

Authors:  J D Dunitz
Journal:  Chem Biol       Date:  1995-11

7.  The contribution of vibrational entropy to molecular association. The dimerization of insulin.

Authors:  B Tidor; M Karplus
Journal:  J Mol Biol       Date:  1994-05-06       Impact factor: 5.469

Review 8.  Biochemical and molecular aspects of the coagulation cascade.

Authors:  E W Davie
Journal:  Thromb Haemost       Date:  1995-07       Impact factor: 5.249

9.  Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component.

Authors:  N L Sanders; S P Bajaj; A Zivelin; S I Rapaport
Journal:  Blood       Date:  1985-07       Impact factor: 22.113

10.  Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets.

Authors:  E L Saenko; D Scandella; A V Yakhyaev; N J Greco
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

View more
  6 in total

1.  In Silico Design of Novel Anticoagulant Peptides targeting Blood Coagulation Factor VIIa.

Authors:  Manal S Q Al-Amri; Khalid Alrasadi; Riad Bayoumi; Yajnavalka Banerjee
Journal:  Sultan Qaboos Univ Med J       Date:  2011-02-12

Review 2.  The chemistry of snake venom and its medicinal potential.

Authors:  Ana L Oliveira; Matilde F Viegas; Saulo L da Silva; Andreimar M Soares; Maria J Ramos; Pedro A Fernandes
Journal:  Nat Rev Chem       Date:  2022-06-10       Impact factor: 34.571

3.  Quantitative Characterization of the Hemorrhagic, Necrotic, Coagulation-Altering Properties and Edema-Forming Effects of Zebra Snake (Naja nigricincta nigricincta) Venom.

Authors:  Erick Kandiwa; Borden Mushonga; Alaster Samkange; Ezequiel Fabiano
Journal:  J Toxicol       Date:  2018-10-24

4.  Assessing the Binding of Venoms from Aquatic Elapids to the Nicotinic Acetylcholine Receptor Orthosteric Site of Different Prey Models.

Authors:  Richard J Harris; Nicholas J Youngman; Christina N Zdenek; Tam M Huynh; Amanda Nouwens; Wayne C Hodgson; David Harrich; Nathan Dunstan; José A Portes-Junior; Bryan G Fry
Journal:  Int J Mol Sci       Date:  2020-10-06       Impact factor: 5.923

5.  A Venomics Approach to the Identification and Characterization of Bioactive Peptides From Animal Venoms for Colorectal Cancer Therapy: Protocol for a Proof-of-Concept Study.

Authors:  Syeda Kiran Shahzadi; Noushad Karuvantevida; Yajnavalka Banerjee
Journal:  JMIR Res Protoc       Date:  2021-12-21

Review 6.  The Search for Natural and Synthetic Inhibitors That Would Complement Antivenoms as Therapeutics for Snakebite Envenoming.

Authors:  José María Gutiérrez; Laura-Oana Albulescu; Rachel H Clare; Nicholas R Casewell; Tarek Mohamed Abd El-Aziz; Teresa Escalante; Alexandra Rucavado
Journal:  Toxins (Basel)       Date:  2021-06-29       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.